Product logins

Find logins to all Clarivate products below.


Type 2 Diabetes | Treatment Algorithms: Claims Data Analysis | US | 2024

Metformin is the most heavily prescribed type 2 diabetes (T2D) drug and dominates the early lines of therapy before disease progression requires insulin replacement. The emergence of more-effective, safer, and better-tolerated therapies, such as sodium-glucose cotransporter 2 (SGLT- 2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) agonists, has provided physicians with a broad array of therapeutic options. Moreover, with a better understanding of T2D and its complications, treatment of the disease is becoming more individualized. Numerous branded agents from both established and recently launched classes are now jostling for position in the treatment paradigm.

Questions answered

  • What patient shares do key therapies garner by line of therapy in newly diagnosed T2D patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed T2D patients?
  • How have Brenzavvy and Mounjaro been integrated into the treatment algorithm, and what are their sources of business?
  • What percentage of T2D patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of T2D patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

Markets covered: United States

Key drugs: Humalog, Jardiance, Lantus, metformin, Mounjaro, Novolog, Ozempic, Rybelsus, Toujeo, Trulicity

Product description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Key feature

Dashboard featuring interactive visuals, easy navigation, and expanded analyses

Related Market Assessment Reports

Report
Human Immunodeficiency Virus – Current Treatment – Treatment Algorithms: Claims Data Analysis – Human Immunodeficiency Virus (US)
The HIV therapy market is crowded with several approved ARVs. Market growth is driven by the increasing acceptance of new, high-priced ARVs, particularly the latest STRs, which offer improved…
Report
Squamous Cell Carcinoma of the Head and Neck – Geographic Focus: China – China In-Depth – Squamous Cell Carcinoma of the Head and Neck
China’s SCCHN market is undergoing rapid transformation, driven by the expanding use of systemic therapies beyond traditional surgery and radiotherapy. Current treatment options include…
Report
Breast Cancer – Geographic Focus: China – China In-Depth – Breast Cancer
China’s breast cancer market continues to evolve rapidly, driven by rising incidence and expanding systemic treatment options. Several new and emerging therapies are expected to gain approval for…
Report
Bladder Cancer and Upper Tract Urothelial Carcinoma – Geographic Focus: China – Bladder Cancer and Upper Tract Urothelial Carcinoma – China In-Depth – China
China’s bladder cancer market is entering a period of accelerated expansion, as novel branded therapies reshape systemic management. A major growth driver is the expanding role of immune…
Report
Major Depressive Disorder (DSM-V) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Major Depressive Disorder (US)
Major depressive disorder (MDD) is a widely drug-treated condition managed with multiple drug classes, most commonly selective serotonin reuptake inhibitors (SSRIs), serotonin–norepinephrine…